…
CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -2.60M | -1.79M | -2.67M | -2.33M | -3.31M |
| Minority interest | - | - | - | - | 0.00M |
| Net income | -3.01M | -1.21M | -2.67M | -2.33M | -3.31M |
| Selling general administrative | 2.60M | 1.79M | 3.08M | 1.98M | 2.15M |
| Gross profit | - | - | - | - | 0.00M |
| Ebit | - | -1.79M | -3.08M | -1.98M | -2.15M |
| Ebitda | -2.60M | -1.79M | -2.88M | -1.98M | -2.15M |
| Depreciation and amortization | - | - | 0.20M | 0.00M | 0.00M |
| Non operating income net other | - | - | - | - | 0.00M |
| Operating income | -2.60M | -1.79M | -3.08M | -1.98M | -2.15M |
| Other operating expenses | 2.60M | 1.79M | 3.08M | 1.98M | 2.15M |
| Interest expense | - | 0.00M | 0.10M | 0.80M | 1.22M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.00M | 0.20M | 0.00M | 0.00M |
| Net interest income | - | 0.00M | 0.10M | -0.80M | -1.22M |
| Extraordinary items | - | - | - | - | 0.00M |
| Non recurring | - | - | - | - | 0.00M |
| Other items | - | - | - | - | 0.00M |
| Income tax expense | 0.41M | -0.58M | - | - | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 2.60M | 1.79M | 3.08M | 1.98M | 2.15M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | - | - | 0.41M | -0.34M | -1.16M |
| Discontinued operations | - | 0.58M | 0.58M | 0.58M | 0.58M |
| Net income from continuing ops | -2.60M | -1.79M | -2.67M | -2.33M | -3.31M |
| Net income applicable to common shares | - | -1.21M | -2.67M | -2.33M | -3.31M |
| Preferred stock and other adjustments | - | - | - | - | 0.00M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 4.79M | 28.74M | 31.24M | 32.40M | 28.75M |
| Other current assets | 0.40M | 25.20M | 24.45M | - | - |
| Total liab | 0.66M | 0.92M | 1.13M | 1.05M | 1.13M |
| Total stockholder equity | 4.12M | 27.82M | 30.11M | 31.35M | 27.62M |
| Other current liab | 0.19M | 0.18M | 0.16M | 0.00M | 0.03M |
| Common stock | 80.79M | 80.79M | 80.45M | 80.45M | 69.51M |
| Capital stock | 80.79M | 80.79M | 80.45M | 80.45M | 69.51M |
| Retained earnings | -80.95M | -40.53M | -37.52M | -36.48M | -34.95M |
| Other liab | - | - | 0.16M | 0.14M | 0.16M |
| Cash | 4.38M | 3.48M | 6.68M | 2.79M | 0.40M |
| Total current liabilities | 0.66M | 0.92M | 1.13M | 0.91M | 0.96M |
| Net debt | -4.38M | -3.48M | -6.68M | -2.79M | -0.40M |
| Short long term debt | - | - | - | 0.00M | 0.00M |
| Other stockholder equity | 4.28M | -12.45M | -12.82M | -12.62M | -6.94M |
| Property plant equipment | - | - | - | 0.45M | 27.38M |
| Total current assets | 4.79M | 28.74M | 31.24M | 3.15M | 0.89M |
| Net tangible assets | - | - | 30.11M | 7.81M | 27.14M |
| Net receivables | 0.40M | 0.06M | 0.11M | 0.01M | 0.03M |
| Inventory | 0.00M | - | 0.00M | 0.21M | 0.28M |
| Accounts payable | 0.47M | 0.74M | 0.97M | 0.91M | 0.96M |
| Accumulated other comprehensive income | 0.00M | - | - | - | - |
| Non currrent assets other | - | - | - | 5.25M | - |
| Non current assets total | 0.00M | 0.00M | 0.00M | 29.25M | 27.87M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.19M | 6.04M | -5.18M | -0.50M | -2.05M |
| Change to liabilities | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Total cashflows from investing activities | - | 6.04M | -5.18M | -0.50M | -2.05M |
| Net borrowings | - | - | -0.11M | -0.34M | 3.45M |
| Total cash from financing activities | 0.34M | - | 9.89M | 1.50M | 3.45M |
| Change to operating activities | - | - | - | - | 0.00M |
| Net income | -3.01M | -1.21M | -2.67M | -2.33M | -3.31M |
| Change in cash | -3.20M | 3.89M | 2.39M | -0.86M | -1.30M |
| Begin period cash flow | 6.68M | 2.79M | 0.40M | 1.26M | 2.56M |
| End period cash flow | 3.48M | 6.68M | 2.79M | 0.40M | 1.26M |
| Total cash from operating activities | - | -1.83M | -2.20M | -1.90M | -2.59M |
| Issuance of capital stock | 0.34M | 0.00M | 10.01M | 1.84M | 0.00M |
| Depreciation | - | 0.28M | 0.01M | 0.01M | 0.01M |
| Other cashflows from investing activities | - | 0.33M | 0.04M | 0.00M | 0.00M |
| Dividends paid | - | - | - | - | 0.00M |
| Change to inventory | - | - | - | - | 0.00M |
| Change to account receivables | - | - | - | - | 0.00M |
| Sale purchase of stock | - | - | - | - | 0.00M |
| Other cashflows from financing activities | -0.19M | 6.04M | 0.61M | 0.49M | -2.05M |
| Change to netincome | - | -0.63M | 0.47M | 0.42M | 0.72M |
| Capital expenditures | 0.33M | 0.43M | 0.56M | 0.50M | 2.05M |
| Change receivables | - | - | - | - | 0.00M |
| Cash flows other operating | - | - | - | - | 0.00M |
| Exchange rate changes | - | - | - | - | 0.00M |
| Cash and cash equivalents changes | - | - | - | - | 0.00M |
| Free cash flow | -0.33M | -0.43M | -0.56M | -0.50M | -2.05M |
Sector: Basic Materials Industry: Other Industrial Metals & Mining
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| BHPLF BHP Group Limited |
- -% |
34.27 | 19.59 | 15.20 | 3.72 | 3.95 | 7.44 |
| BHP BHP Group Limited |
-1.32 1.93% |
67.23 | 19.28 | 15.06 | 3.66 | 3.92 | 7.42 |
| RTNTF Rio Tinto Group |
- -% |
91.08 | 15.69 | 13.70 | 3.05 | 4.44 | 12.05 |
| RTPPF Rio Tinto Group |
- -% |
74.61 | 13.01 | 11.99 | 2.53 | 2.38 | 6.57 |
CRISM Therapeutics Corporation focuses on drug delivery technology to improve the clinical performance of cancer drugs as treatments for solid tumors. Its lead product, ChemoSeed that can be implanted directly into a tumor or the resection margin following the removal of a tumor, ensuring effective therapeutic concentrations of chemotherapy drugs directly reach the tumor tissue. Its ChemoSeed used for treatment of gliomas, a brain tumor. The company was founded in 2016 and is based in Road Town, the British Virgin Islands.
| Name | Title | Year Born |
|---|---|---|
| Mr. Robin Jay Young | CEO, Sec. & Exec. Director | 1955 |
| Mr. Ae Jack Swanson | Chief Operating Officer | 1938 |
| Mr. Robin Jay Young | CEO, Secretary & Executive Director | 1955 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.